HCPLive Network

Plaque Psoriasis

The National Psoriasis Foundation (NPF) announced in a press release that the Centers for Medicare and Medicaid Services will not cut reimbursement for phototherapy in 2015.
Many studies that inform current international guidelines for the treatment of psoriatic arthritis (PsA) are of poor quality and lack applicability in clinical practice.
The US Food and Drug Administration recently announced its approval of a new medication for the treatment of rheumatoid arthritis.
For patients with moderate-to-severe plaque psoriasis, the fully human anti-interleukin-17A monoclonal antibody, secukinumab, is effective, according to research published online July 9 in the New England Journal of Medicine.
Individuals with hypertension and those with long-term, regular use of beta-blocker medication may be at increased risk of developing psoriasis flares, according to research published online July 2 in JAMA Dermatology.
Study results show that treatment with etanercept is effective and well tolerated in adolescent patients with psoriatic arthritis and other rheumatic conditions.
Plaque Psoriasis Upcoming Events
Paris, France
June 11-14, 2014
New York, NY
July 9-12, 2014
Chicago, IL
August 6-10, 2014
Louisville, KY
August 7-9, 2014
Las Vegas, NV
September 12-13, 2014
Sonoma, CA
September 24-27, 2014
Las Vegas, NV
October 16-19, 2014
Dallas, TX
October 24-26, 2014
Boston, MA
November 14-19, 2014
New Orleans, LA
April 27-29, 2015
Plaque Psoriasis Latest News
Plaque Psoriasis Clinical Trials